A year ago, Novartis inked a high-profile partnership with tech giant Qualcomm to develop a smart inhaler, in a clear bid to compete with its chief rival in the respiratory market, GlaxoSmithKline, which had formed a similar partnership with Propeller Health.
But now a report out of India suggests Novartis may be looking to retreat from the increasingly competitive market for asthma and COPD drugs and is seeking to sell off some brands.
India’s Economic Times, quoting anonymous sources, reports that Novartis is weighing offers for its respiratory portfolio from top India-based generic drugmakers, including Cipla, Zydus Cadila, Sun Pharmaceutical and Lupin. The portfolio could be worth up to $500 million, the sources said, and it includes Tobi Podhaler, a drug to treat cystic fibrosis.
A spokesman for Novartis said the company does not comment on “rumors and speculation” and that it remains committed to its pipeline of respiratory drugs.
Novartis is certainly no stranger to casting off products to raise cash. Last March, Sun shelled out $293 million to acquire 14 brands that Novartis sold in Japan, a market where it had struggled to thrive. Before that, Novartis pulled off an asset trade with GSK and sold off its animal health unit to Eli Lilly.
In December of last year, rumors emerged suggesting that Novartis was looking to divest its older central nervous system drugs for as much as $496 million, including Exelon to treat Alzheimer’s and the ADD treatment Ritalin. That sale hasn’t happened, and CEO Joe Jimenez has repeatedly cited CNS as a priority for Novartis’ pipeline. Novartis Chairman Joerg Reinhardt sparked speculation about the company’s eye unit, Alcon, late last year, when he commented that the business has been struggling for two years and that divesting it might be the best option. But that hasn’t happened yet, either.
As for Novartis’ respiratory portfolio, the company has three asthma compounds in phase 3 trials and a cystic fibrosis drug in phase 2. And it is collaborating with Qualcomm Life to develop the next generation version of its Breezhaler, the inhaler used with its COPD meds. The product will record real-time data from patients, such as when the inhaler is being used, and beam it to the cloud and smartphones to enable better coordination between patients and their doctors.
The Novartis spokesman says the collaboration is ongoing. Maybe so, but it’s clear the company is having some struggles in the respiratory market. In December, it announced it was out-licensing three of its COPD products to Sunovion for commercialization in the U.S. “Given the evolving market dynamics, we believe these products will have the greatest impact in the U.S. when commercialized by a company with an established presence in the COPD field,” said Fabrice Chouraqui, president of Novartis, in a statement at the time.
And Novartis is clearly under pressure across its entire portfolio. In 2016, the company’s sales volume rose 6% year-over-year but net sales fell 2%, as pricing pressure took its toll. Jimenez warned investors during a conference call that 2017 would “look a lot like 2016.” Selling off assets, particularly Alcon, could be a good short-term Band-Aid. The company is expected to make a decision about Alcon by the end of this year.
By Arlene Weintraub
Source: Fierce Pharma
Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.
The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.